Overview
The Retatrutide 30mg vial provides the triple GLP-1/GIP/glucagon receptor agonist at Nova Biolabs' best value per milligram. As one of the most studied next-generation peptide compounds in current research, Retatrutide's triple receptor mechanism continues to generate significant scientific interest globally.
Held in Indonesia domestic stock, HPLC-verified at >98% purity, and dispatched with fast, discreet packaging.
Retatrutide 30mg is currently in stock and available for research order with domestic dispatch from Indonesia.
Key Research Areas
Extended Triple-Receptor Studies
The 30mg vial is ideal for research programmes requiring sustained access to the triple-agonist compound over multiple experimental runs.
GLP-1, GIP and Glucagon Receptor Co-Activation
Studying the simultaneous activation of all three receptors and their downstream intracellular signalling pathways is a key focus of current metabolic research.
Hepatic Glucose Research
The glucagon receptor component of Retatrutide is particularly relevant to research examining hepatic glucose output, glycogenolysis, and gluconeogenesis signalling.
Adipose and Thermogenesis Research
Investigated in fat cell models for its interactions with adipogenesis signalling and thermogenic pathway activation.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 30mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | Indonesia domestic stock |
| Research use | In vitro / laboratory use only |
| Availability | In Stock |
Published batch report
Batch RETA30-2607-01 · Measured content 33.48mg · Purity 99.754% · Analysed by Janoshik Analytical on 29 July 2026.
This result applies only to Retatrutide 30mg batch RETA30-2607-01.
Verify task #210009 directly with Janoshik →